The FDA approved Johnson & Johnson’s application for non-prescription Zyrtec-D (because of the D, it's not actually OTC - more like the trendy BTC). The product will now compete head-to-head against Claritin-D. Given the consumer marketing muscle of J&J and P&G, this is a ballgame to watch.
By the way, like most J&J announcements, they didn’t announce it – even on their unofficial official unofficial blog. Like most folks we learned about it from the FDA. I know the FDA has a lot on its plate these days, but I would like to thank them for helping out the J&J communications team.